Methoden vergleichen
Prüfen Sie die ausgewählten Methoden nebeneinander; abweichende Zeilen sind hervorgehoben.
| EORTC QLQ-C15-PAL: Lebensqualität in der palliativen Krebstherapie× | EORTC QLQ-BR23: Lebensqualität bei Brustkrebs× | |
|---|---|---|
| Fachgebiet | Onkologie | Onkologie |
| Familie | Process / pipeline | Process / pipeline |
| Entstehungsjahr≠ | 2006 | 1996 |
| Urheber≠ | Groenvold, M., et al. (EORTC Quality of Life Group) | Sprangers, M. A., et al. (EORTC Quality of Life Group) |
| Typ | Self-report questionnaire | Self-report questionnaire |
| Wegweisende Quelle≠ | Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, J. M., Bottomley, A., et al. (2006). The development of the EORTC QLQ-C15-PAL: a shortened quality-of-life questionnaire for cancer patients in palliative care. Eur J Cancer, 42(1), 55–64. DOI ↗ | Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., et al. (1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol, 14(10), 2756–2768. DOI ↗ |
| Aliasnamen | QLQ-C15-PAL | QLQ-BR23 |
| Verwandt | 5 | 5 |
| Zusammenfassung≠ | The EORTC QLQ-C15-PAL is a 15-item quality-of-life instrument specifically designed for advanced cancer patients receiving palliative care. Developed by Groenvold et al. in 2006, it is a shortened version of the QLQ-C30, retaining core QoL domains while reducing respondent burden—critical in palliative settings where fatigue and functional impairment limit questionnaire completion. It measures physical, emotional, and functional well-being alongside key palliative symptoms. | The EORTC QLQ-BR23 is a 23-item breast-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire, assessing functional and symptom domains unique to breast cancer. Validated by Sprangers et al. in 1996, it measures body image, sexual function, breast symptoms, and arm symptoms, making it a standard instrument in European and international breast cancer clinical trials and quality-of-life research. |
| ScholarGateDatensatz ↗ |
|
|